EU regulator backs use of GSK's RSV shot in adults aged 50 to 59
Adds background throughout
July 26 (Reuters) -The European Union health regulator on Friday recommended expanded use of GSK's GSK.L respiratory syncytial virus (RSV) vaccine in adults aged between 50 and 59.
Any recommendation by the European Medicines Agency's Committee for Medicinal Products for Human Use has to be formally approved by the European Commission, which usually follows the regulator's decision.
The vaccine, branded Arexvy, was approved by the U.S. Food and Drug Administration in June but the Centers for Disease Control and Prevention (CDC) did not recommend RSV shots for adults under 60 years.
The CDC had recommended that adults aged 75 and older, as well as those between the ages of 60 and 74 at an increased risk of severe RSV due to medical conditions, should receive shots against the virus.
The recommendation downsized GSK's U.S. market for the shot in 2024-25 from 93 million to about 55 million, according to analysts.
GSK had forecast peak annual sales of more than 3 billion pounds for the vaccine.
Reporting by Prerna Bedi in Bengaluru; Editing by Shounak Dasgupta
Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
